SPRUCE BIOSCIENCES, INC.
About SPRUCE BIOSCIENCES, INC.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$39.0M
- Total assets
- $53.0M
- Market cap
- $138.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $36.5M
- Operating income
- -$36.5M
- Income tax
- $0
- Net income
- -$39.0M
- EPS (basic)
- $-50.83
- EPS (diluted)
- $-50.83
Balance sheet
- Total assets
- $53.0M
- Current assets
- $52.1M
- Total liabilities
- $10.5M
- Current liabilities
- $10.1M
- Shareholders’ equity
- $42.5M
Cash flow
- Operating cash flow
- -$33.3M
- Investing cash flow
- -$10.2M
- Financing cash flow
- $43.5M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $138.8M
- EPS (diluted)
- $-50.83
- Shares outstanding
- 2.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 9, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $39.0M in FY2025.
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SPRUCE BIOSCIENCES, INC..
Write a review
News about SPRUCE BIOSCIENCES, INC.
News & sentiment via Polygon.io
